Hospital Ruber Internacional
The doctor is an M.D., Ph.D., Ophthalmologist specializing in macula and vitreorretinal conditions. Known for significant contributions to ophthalmology, the doctor has advanced macular degeneration imaging techniques and treatment protocols. With a focus on pathophysiology, imaging, and emerging therapies for AMD and retinal degenerative diseases, the doctor has completed specialized training in ophthalmology at the Universitat Autònoma de Barcelona and fellowships at Harvard University and the Instituto Tecnológico y de Estudios Superiores de Monterrey.
The doctor is a Research Member Elect of the International Alliance AMD and a scientific adviser to the European Association for Vision and Eye Research. Memberships include 12 scientific societies such as the Macula Society and The Retina Society.
The doctor has focused research on paraneoplastic neurological syndromes, leading a panel that established diagnostic criteria. His work confirmed the immune hypothesis linking tumors to autoimmune neurological dysfunctions, with antibodies identified by him now essential for diagnosis.
Clinically, the doctor specializes in diagnosing and managing gliomas, primary brain lymphomas, and cancer treatment-related neurotoxicities. Recent interests include neurological complications from immune checkpoint inhibitors and hematopoietic stem cell transplantation.
He holds an MD and PhD from Universitat Autónoma de Barcelona, completed a neurology residency in Barcelona, and a neuro-oncology fellowship at Memorial Sloan-Kettering Cancer Center.
The doctor is a highly skilled neurosurgeon specializing in the treatment of brain tumors. With extensive experience in both surgical and non-surgical approaches, the doctor has contributed significantly to advancements in neuro-oncology. The doctor is recognized for implementing cutting-edge techniques and has published numerous research papers in leading medical journals. The doctor is committed to improving patient outcomes through innovative treatment strategies and is actively involved in clinical trials aimed at developing new therapies for brain tumor patients.
Optic nerve atrophy treatment in Spain focuses on neuroprotection and managing underlying causes to halt vision loss. Specialized centers use advanced microsurgery for decompression and intraocular pressure control. Patients access neuro-ophthalmological programs providing medical management, electrical stimulation, and innovative visual cortex brain implants in research settings.
Bookimed Expert Insight: Spanish healthcare is uniquely organized around large JCI-accredited hubs like Centro Médico Teknon or Hospital Ruber Internacional. These centers combine neurosurgery and ophthalmology departments under one roof. This proximity is vital for atrophy caused by tumors or aneurysms. It allows surgical decompression to occur within hours of diagnosis. Our data shows these integrated facilities handle over 20,000 cases annually, ensuring high proficiency in preserving remaining vision.
Patient Consensus: Patients emphasize the need for a full workup to find the root cause, such as B12 deficiency or glaucoma. They note that practical low-vision rehabilitation is essential once vision loss is established.
Stem cell therapy for optic nerve atrophy is not currently available as a standard treatment in Spanish clinics. While Spain leads in regenerative medicine, regulatory frameworks limit these therapies to official clinical trials. Standard care focuses on managing underlying causes through advanced diagnostics at accredited facilities.
Bookimed Expert Insight: Spanish healthcare maintains rigorous standards with 83 clinics often holding JCI and ISO certifications. While high-profile centers like Centro Médico Teknon use advanced stem cell therapy for trauma recovery, they do not offer it for vision restoration. Patients should prioritize clinics with these specific global accreditations over those making unverified regenerative claims.
Patient Consensus: Patients emphasize the need to distinguish between experimental trials and paid elective procedures. Many note that reputable specialists often caution against any clinic promising full vision recovery without published outcome data.
Barcelona and Pamplona are the leading Spanish hubs for advanced optic nerve atrophy care. These cities host JCI-accredited centers providing specialized neuro-ophthalmology and molecular medicine. Primary clinics include Centro Médico Teknon, SJD Barcelona Children's Hospital, and Clínica Universidad de Navarra, which focus on neuroprotection and diagnostic precision.
Bookimed Expert Insight: Spanish medical centers like Clinica Universidad de Navarra and Centro Médico Teknon manage extremely high patient volumes, exceeding 100,000 cases annually. This scale allows them to maintain JCI standards while offering rare access to international clinical trials. Patients should prioritize clinics in Barcelona for their density of specialized pediatric and neurological centers.
Patient Consensus: Patients emphasize requesting a direct neuro-ophthalmology referral rather than general eye care. They also recommend bringing all prior MRI reports and OCT scans to avoid diagnostic delays.
Visual improvement after stem cell therapy typically begins within 1 to 3 months. Most substantial changes occur between 6 and 12 months post-procedure. This regenerative process requires time to integrate cells and rebuild damaged ocular tissues. Long-term consolidation may continue for 18 months.
Bookimed Expert Insight: Spain is a hub for specialized regenerative medicine. Clinics like Centro Médico Teknon treat high-profile individuals and professional athletes. Their experience with biological therapies suggests that clinics managing over 10,000 patients annually offer the most refined protocols. This high volume often leads to better-standardized recovery monitoring for neurological conditions.
Patient Consensus: Patients note that early improvements are often subtle, such as better light perception or contrast. It is common to wait at least 3 to 6 months before seeing definitive changes in vision clarity.
Success rates for stem cell therapy vary significantly by medical condition and treatment intent. Hematopoietic stem cell transplants for blood cancers report 40% to 70% 5-year survival. Regenerative orthopedic procedures show symptom improvement in 70% to 85% of patients within 12 months of treatment.
Bookimed Expert Insight: Spanish clinics like Centro Médico Teknon focus on high-volume specialty care for elite athletes. While success in optic nerve cases is experimental, these centers excel in trauma recovery using mesenchymal cells. Choosing a facility with JCI accreditation ensures clinical protocols follow established international safety standards.
Patient Consensus: Patients emphasize the need for baseline ophthalmology tests like OCT to objectively track any changes. Most note that improvements in optic nerve cases are often modest rather than a complete cure.
Stem cell therapy for optic nerve atrophy in Spain is safe when performed within approved clinical trials. Spanish facilities follow strict European Union regulations for Advanced Therapy Medicinal Products. Centers undergo rigorous inspections to ensure procedures meet high medical and ethical standards.
Bookimed Expert Insight: Spain attracts patients because top centers like Centro Médico Teknon integrate stem cell research into established departments. This clinic serves over 10,000 patients annually and provides official medical support for elite athletes. Our data shows that high-volume centers with JCI accreditation use standardized protocols to minimize risks during experimental treatments.
Patient Consensus: Patients note it is important to verify that a procedure is part of a formal trial. While they find Spanish hospitals professional, they emphasize that a low-risk procedure does not always guarantee restored vision.
Ideal candidates for regenerative therapy in Spain include individuals with mild-to-moderate degenerative conditions or sports injuries. Spain strictly regulates advanced therapies through the Spanish Agency for Medicines and Medical Products. Eligibility depends on cellular health and the absence of active infections or tumors.
Bookimed Expert Insight: Spain’s medical infrastructure provides a unique advantage for pediatric cases and complex recoveries. SJD Barcelona Children’s Hospital manages over 450,000 patients annually, offering specialized regenerative paths for minors. Meanwhile, Centro Médico Teknon utilizes advanced protocols even for elite athletes from FC Barcelona. Patients should look for JCI-accredited facilities like Clinica Universidad de Navarra, which was the first in Spain to secure this quality mark.